Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioAtla (BCAB) Net Margin (2020 - 2025)

BioAtla's Net Margin history spans 4 years, with the latest figure at 459.1% for Q4 2025.

  • For Q4 2025, Net Margin changed N/A year-over-year to 459.1%; the TTM value through Dec 2025 reached 2923.3%, down 228172.0%, while the annual FY2025 figure was 2923.1%, 228152.0% down from the prior year.
  • Net Margin reached 459.1% in Q4 2025 per BCAB's latest filing, down from 96.16% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 96.16% in Q3 2024 to a low of 12152.4% in Q2 2021.
  • Average Net Margin over 3 years is 4235.89%, with a median of 459.1% recorded in 2025.
  • The largest YoY upside for Net Margin was -887766bps in 2021 against a maximum downside of -887766bps in 2021.
  • A 3-year view of Net Margin shows it stood at 12152.4% in 2021, then soared by 99bps to 96.16% in 2024, then crashed by -377bps to 459.1% in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Net Margin are 459.1% (Q4 2025), 96.16% (Q3 2024), and 12152.4% (Q2 2021).